Shijiazhuang Yiling Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Shijiazhuang Yiling Pharmaceutical Co Ltd cash flow reinvestment rate. Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) has a Cash Flow Reinvestment Rate of 0.19x as of September 2025, reinvesting CN¥84.38 Million (capex CN¥84.38 Million ) from operating cash flow of CN¥446.51 Million. Explore how well can Shijiazhuang Yiling Pharmaceutical Co Lt service its debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2025)
Cash flow reinvestment rate of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2025. Historical reinvestment intensity for Shijiazhuang Yiling Pharmaceutical Co Ltd across 17 annual periods. Explore how much does Shijiazhuang Yiling Pharmaceutical Co Lt reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
Shijiazhuang Yiling Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2008–2025)
Shijiazhuang Yiling Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2008 to 2025. Year-by-year capital reinvestment analysis for Shijiazhuang Yiling Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Shijiazhuang Yiling Pharmaceutical Co Lt (002603) cash conversion ratio.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.56x | CN¥1.00 Billion | CN¥1.78 Billion | CN¥245.62 Million | ▼ -84.3% |
| 2024 | 3.59x | CN¥2.19 Billion | CN¥611.01 Million | CN¥290.39 Million | ▼ -53.9% |
| 2023 | 7.78x | CN¥1.21 Billion | CN¥155.46 Million | CN¥310.83 Million | ▲ +1129.1% |
| 2022 | 0.63x | CN¥2.21 Billion | CN¥3.49 Billion | CN¥213.98 Million | ▼ -59.8% |
| 2021 | 1.58x | CN¥832.89 Million | CN¥528.69 Million | CN¥673.56 Million | ▲ +104.2% |
| 2020 | 0.77x | CN¥1.22 Billion | CN¥1.59 Billion | CN¥1.14 Billion | ▼ -94.2% |
| 2019 | 13.23x | CN¥912.02 Million | CN¥68.93 Million | CN¥454.43 Million | ▲ +147.9% |
| 2018 | 5.34x | CN¥386.34 Million | CN¥72.37 Million | CN¥187.23 Million | ▼ -36.7% |
| 2017 | 8.43x | CN¥966.75 Million | CN¥114.65 Million | CN¥180.35 Million | ▲ +516.0% |
| 2016 | 1.37x | CN¥877.97 Million | CN¥641.45 Million | CN¥373.03 Million | ▼ -78.6% |
| 2015 | 6.41x | CN¥845.18 Million | CN¥131.88 Million | CN¥478.43 Million | ▲ +50.8% |
| 2014 | 4.25x | CN¥450.19 Million | CN¥105.90 Million | CN¥450.19 Million | ▼ -42.6% |
| 2013 | 7.41x | CN¥409.83 Million | CN¥55.32 Million | CN¥409.83 Million | ▲ +75.0% |
| 2012 | 4.23x | CN¥296.89 Million | CN¥70.13 Million | CN¥296.89 Million | ▲ +345.2% |
| 2010 | 0.95x | CN¥285.02 Million | CN¥299.72 Million | CN¥285.02 Million | ▲ +43.7% |
| 2009 | 0.66x | CN¥210.57 Million | CN¥318.21 Million | CN¥210.57 Million | ▲ +8.4% |
| 2008 | 0.61x | CN¥128.27 Million | CN¥210.18 Million | CN¥128.27 Million | — |